RECOMBINATE 500 IU
Country: Ísrael
Tungumál: enska
Heimild: Ministry of Health
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
COAGULATION FACTOR VIII RECOMBINANT 500 IU/VIAL
Fáanlegur frá:
TEVA MEDICAL MARKETING LTD.
ATC númer:
B02BD05
Lyfjaform:
POWDER FOR SOLUTION FOR INJECTION
Stjórnsýsluleið:
I.V
Framleitt af:
BAXTER S.A., BELGIUM
Meðferðarhópur:
COAGULATION FACTOR VII
Ábendingar:
The use of Recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Recombinate is also indicated in the perioperative management of patients with haemophilia A. Recombinate is appropriate for use in children of all ages including the newborn. (Safety and efficacy studies have been performed in both previously treated and previously untreated children). The product in not suitable for the treatment of von Willebrand's disease.
Leyfisdagur:
2010-07-01
